Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Cirius Therapeutics logo — Pioneering the future of liver and metabolic disease treatme...

Cirius Therapeutics

Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.

Founded 2015 Series A Total: $49.00M Biopharma, Biotechnology +3

General Information

Company Name Cirius Therapeutics
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biopharma, Biotechnology, Health and Wellness +2
Funding Stage Series A
Social

Get notified when Cirius Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cirius Therapeutics

Cirius Therapeutics is a clinical-stage company focused on developing treatments for non-alcoholic steatohepatitis (NASH). They are pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers. The company's flagship product, MSDC-0602K, a next-generation insulin sensitizer, is currently in a Phase 2b clinical trial. This drug aims to address the root cause of NASH through a novel insulin-sensitizing mechanism. Founded in 2015 and headquartered in Kalamazoo, Michigan, Cirius Therapeutics is dedicated to creating innovative therapies for liver and metabolic diseases. The company secured a $9.00M Series A investment on 30 August 2018 with funding from notable investors including Novo Holdings, Adams Street Partners, and Frazier Healthcare Partners. With its focus on high-impact biopharmaceuticals and a strong track record in the health and wellness industry, Cirius Therapeutics is poised for growth and potential breakthroughs in the treatment of liver and metabolic diseases.

Taxonomy: Cirius Therapeutics, insulin sensitizer, MSDC-0602K, non-alcoholic steatohepatitis, NASH treatment, liver disease, metabolic disease, clinical-stage company, Phase 2b clinical trial, innovative therapies, pathophysiology, biopharmaceutical industry, clinical research, drug development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor Investor Investor
30 Aug 2018
Series A •••••• 5
Investor Investor Investor Investor Investor
11 Apr 2017

Cirius Therapeutics Alternatives & Competitors

Cirius Therapeutics vs
vTv Therapeutics
vTv Therapeutics United States

Committed to Improving the Lives of Patients with Diabetes

Post Ipo Equity
50 employees
Biotechnology, Health Care
Cirius Therapeutics vs
Lucas Research
Lucas Research United States

Committed to moving medicine forward.

35 employees
Health Care
Cirius Therapeutics vs
IMIC Medical Research, a Rovia Clinical Research Company
IMIC Medical Research, a Rovia Clinical Research Company United States

A Medical Research clinic working in Alzheimer's studies, IBD, Vaccines, NASH/MASH,Asthma, COPD, Dia...

6 employees
Health Care

FAQ About Cirius Therapeutics

Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.
Cirius Therapeutics was founded in 2015.
Cirius Therapeutics operates in the following industries: Biopharma, Biotechnology, Health and Wellness, Medical Devices, Pharmaceutical.
Cirius Therapeutics has completed 2 funding rounds, raising a total of $49.00M. The latest funding stage is Series A.
Top alternatives and competitors to Cirius Therapeutics include vTv Therapeutics, Lucas Research, IMIC Medical Research, a Rovia Clinical Research Company, NorthSea Therapeutics, Atom Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cirius Therapeutics and vTv Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cirius Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy